Abstract
Hidradenitis suppurativa/acne inversa (HS) is a chronic, recurrent skin disease of the hair follicle, which only occurs in humans. We have developed an ex vivo HS 3D-SeboSkin model to study the underlying pathophysiology of the disease and test potential therapeutic compounds in a preclinical setting. Adalimumab, a tumor necrosis factor-α inhibitor, is approved for treatment of moderate to severe HS. In this work, we investigated the anti-inflammatory effect of Adalimumab in the HS 3D-SeboSkin model and evaluated the regulation of HS biomarkers under Adalimumab treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
